+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Thyroid Cancer - Pipeline Review, H2 2019

  • ID: 4866574
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 825 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Aslan Pharmaceuticals Ltd
  • Celldex Therapeutics Inc
  • Exelixis Inc
  • Johnson & Johnson
  • Novartis AG
  • Tarveda Therapeutics Inc
  • MORE
Thyroid Cancer - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Thyroid Cancer - Pipeline Review, H2 2019, provides an overview of the Thyroid Cancer (Oncology) pipeline landscape.

Thyroid cancer is a cancer that starts in the thyroid gland. Symptoms include lump that can be felt through the skin on neck, difficulty swallowing, pain in neck and throat and swollen lymph nodes in neck. Predisposing factors include female, high levels of radiation and inherited genetic syndromes. Treatment includes surgery and thyroid hormone therapy.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Thyroid Cancer - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Thyroid Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thyroid Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Thyroid Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 39, 33, 3, 18, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 7 and 2 molecules, respectively.

Thyroid Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Thyroid Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Thyroid Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Thyroid Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Thyroid Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Thyroid Cancer (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Thyroid Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Thyroid Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Aslan Pharmaceuticals Ltd
  • Celldex Therapeutics Inc
  • Exelixis Inc
  • Johnson & Johnson
  • Novartis AG
  • Tarveda Therapeutics Inc
  • MORE
Introduction
Thyroid Cancer - Overview
Thyroid Cancer - Therapeutics Development
Thyroid Cancer - Therapeutics Assessment
Thyroid Cancer - Companies Involved in Therapeutics Development
Thyroid Cancer - Drug Profiles
Thyroid Cancer - Dormant Projects
Thyroid Cancer - Discontinued Products
Thyroid Cancer - Product Development Milestones
Appendix

List of Tables
Table 1: Number of Products under Development for Thyroid Cancer, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 5: Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Table 6: Number of Products under Development by Universities/Institutes, H2 2019
Table 7: Products under Development by Companies, H2 2019
Table 8: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 9: Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 10: Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Table 11: Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Table 12: Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Table 13: Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Table 14: Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Table 15: Products under Development by Universities/Institutes, H2 2019
Table 16: Number of Products by Stage and Target, H2 2019
Table 17: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Table 18: Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Table 19: Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
Table 20: Number of Products by Stage and Mechanism of Action, H2 2019
Table 21: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Table 22: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Table 23: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
Table 24: Number of Products by Stage and Route of Administration, H2 2019
Table 25: Number of Products by Stage and Molecule Type, H2 2019
Table 26: Thyroid Cancer - Pipeline by Advanced Accelerator Applications SA, H2 2019
Table 27: Thyroid Cancer - Pipeline by Advenchen Laboratories LLC, H2 2019
Table 28: Thyroid Cancer - Pipeline by AffyImmune Therapeutics Inc, H2 2019
Table 29: Thyroid Cancer - Pipeline by Aslan Pharmaceuticals Ltd, H2 2019
Table 30: Thyroid Cancer - Pipeline by AstraZeneca Plc, H2 2019
Table 31: Thyroid Cancer - Pipeline by Bayer AG, H2 2019
Table 32: Thyroid Cancer - Pipeline by BeiGene Ltd, H2 2019
Table 33: Thyroid Cancer - Pipeline by BioMed Valley Discoveries Inc, H2 2019
Table 34: Thyroid Cancer - Pipeline by Biovista Inc, H2 2019
Table 35: Thyroid Cancer - Pipeline by Blueprint Medicines Corp, H2 2019
Table 36: Thyroid Cancer - Pipeline by BNOAT Oncology Inc, H2 2019
Table 37: Thyroid Cancer - Pipeline by Boehringer Ingelheim International GmbH, H2 2019
Table 38: Thyroid Cancer - Pipeline by Boston Pharmaceuticals Inc, H2 2019
Table 39: Thyroid Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2019
Table 40: Thyroid Cancer - Pipeline by Celgene Corp, H2 2019
Table 41: Thyroid Cancer - Pipeline by Celldex Therapeutics Inc, H2 2019
Table 42: Thyroid Cancer - Pipeline by Cello Therapeutics Inc, H2 2019
Table 43: Thyroid Cancer - Pipeline by Centrose LLC, H2 2019
Table 44: Thyroid Cancer - Pipeline by CSPC Pharmaceutical Group Ltd, H2 2019
Table 45: Thyroid Cancer - Pipeline by CytImmune Sciences Inc, H2 2019
Table 46: Thyroid Cancer - Pipeline by Cytori Therapeutics Inc, H2 2019
Table 47: Thyroid Cancer - Pipeline by Daiichi Sankyo Co Ltd, H2 2019
Table 48: Thyroid Cancer - Pipeline by Debiopharm International SA, H2 2019
Table 49: Thyroid Cancer - Pipeline by Ecrins Therapeutics SAS, H2 2019
Table 50: Thyroid Cancer - Pipeline by Eisai Co Ltd, H2 2019
Table 51: Thyroid Cancer - Pipeline by Eli Lilly and Co, H2 2019
Table 52: Thyroid Cancer - Pipeline by Exelixis Inc, H2 2019
Table 53: Thyroid Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Table 54: Thyroid Cancer - Pipeline by Genelux Corp, H2 2019
Table 55: Thyroid Cancer - Pipeline by Genmab A/S, H2 2019
Table 56: Thyroid Cancer - Pipeline by Gradalis Inc, H2 2019
Table 57: Thyroid Cancer - Pipeline by Hutchison MediPharma Ltd, H2 2019
Table 58: Thyroid Cancer - Pipeline by ImmunoForge Co Ltd, H2 2019
Table 59: Thyroid Cancer - Pipeline by Immunomedics Inc, H2 2019
Table 60: Thyroid Cancer - Pipeline by IngenoVax LLC, H2 2019

List of Figures
Figure 1: Number of Products under Development for Thyroid Cancer, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Top 10 Targets, H2 2019
Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 8: Number of Products by Top 10 Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Figure 10: Number of Products by Top 10 Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Advanced Accelerator Applications SA
  • Advenchen Laboratories LLC
  • AffyImmune Therapeutics Inc
  • Aslan Pharmaceuticals Ltd
  • AstraZeneca Plc
  • Bayer AG
  • BeiGene Ltd
  • BioMed Valley Discoveries Inc
  • Biovista Inc
  • Blueprint Medicines Corp
  • BNOAT Oncology Inc
  • Boehringer Ingelheim International GmbH
  • Boston Pharmaceuticals Inc
  • Bristol-Myers Squibb Co
  • Celgene Corp
  • Celldex Therapeutics Inc
  • Cello Therapeutics Inc
  • Centrose LLC
  • CSPC Pharmaceutical Group Ltd
  • CytImmune Sciences Inc
  • Cytori Therapeutics Inc
  • Daiichi Sankyo Co Ltd
  • Debiopharm International SA
  • Ecrins Therapeutics SAS
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Exelixis Inc
  • F. Hoffmann-La Roche Ltd
  • Genelux Corp
  • Genmab A/S
  • Gradalis Inc
  • Hutchison MediPharma Ltd
  • ImmunoForge Co Ltd
  • Immunomedics Inc
  • IngenoVax LLC
  • Innovative Cellular Therapeutics Co Ltd
  • Intensity Therapeutics Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • Johnson & Johnson
  • Kemimedi Co Ltd
  • Kitov Pharma Ltd
  • Konruns Pharmaceutical Co Ltd
  • Loxo Oncology Inc
  • MacroGenics Inc
  • MaxiVAX SA
  • Merck & Co Inc
  • Mersana Therapeutics Inc
  • Millennium Pharmaceuticals Inc
  • NantCell Inc
  • Novartis AG
  • Ono Pharmaceutical Co Ltd
  • Pfizer Inc
  • Plexxikon Inc
  • PRISM Pharma Co Ltd
  • QED Therapeutics Inc
  • Recordati SpA
  • Rodos BioTarget GmbH
  • Savoy Pharmaceuticals Inc
  • Sino Biopharmaceutical Ltd
  • SpringWorks Therapeutics Inc
  • Suzhou SmartNuclide Biopharmaceutical Co Ltd
  • Suzhou Zelgen Biopharmaceutical Co Ltd
  • Synactix Pharmaceuticals Inc
  • Tarveda Therapeutics Inc
  • Tmunity Therapeutics Inc
  • Turning Point Therapeutics Inc
  • Tyme Technologies Inc
  • UBI Pharma Inc
  • UbiVac LLC
  • Vaccinex Inc
  • Vascular Biogenics Ltd
  • Veana Therapeutics LLC
  • Xiangxue Life Sciences
  • Xspray Pharma AB
  • Xynomic Pharmaceuticals Holdings Inc
Note: Product cover images may vary from those shown
Adroll
adroll